Related Experiment Video

Updated: Apr 27, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

8.9K

Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma

Justin W Ady1, Jacqueline Heffner1, Kelly Mojica1

  • 1Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.

Surgery
|June 25, 2014
PubMed
Abstract

Insights

Oncolytic vaccinia virus GLV-1h68 effectively kills hepatocellular carcinoma (HCC) cells, including those resistant to sorafenib. This suggests oncolytic virotherapy is a viable option for patients who have not responded to standard HCC treatments.

Area of Science:

  • Oncology
  • Virology
  • Cancer Therapeutics

Background:

  • Hepatocellular carcinoma (HCC) lacks effective treatments, with sorafenib offering minimal survival benefit for advanced or recurrent cases.
  • Novel therapeutic strategies are crucial for improving outcomes in HCC patients.
  • Oncolytic viruses represent a promising approach, selectively targeting and destroying cancer cells.

Purpose of the Study:

  • To evaluate the efficacy of GLV-1h68, a recombinant vaccinia virus, against sorafenib-resistant (SR) HCC cell lines.
  • To determine if GLV-1h68 can overcome sorafenib resistance in HCC.

Main Methods:

  • Generation of four sorafenib-resistant (SR) HCC cell lines through prolonged sorafenib exposure.
  • Assessment of GLV-1h68 infectivity, viral replication, and cytotoxicity in both parental and SR HCC cells.
  • Determination of median inhibitory concentrations for sorafenib across all cell lines.

Main Results:

  • GLV-1h68 demonstrated time- and concentration-dependent infectivity in all tested HCC cell lines.
  • Efficient replication of the vaccinia virus was observed in both parental and SR HCC cells.
  • No significant difference in the rate of cell death was noted between parental and sorafenib-resistant HCC cells.

Conclusions:

  • The oncolytic vaccinia virus GLV-1h68 exhibits potent and efficient killing of both sorafenib-sensitive and sorafenib-resistant HCC cell lines.
  • These findings support the potential of GLV-1h68 as an oncolytic therapy for HCC patients, including those who have progressed on or are resistant to sorafenib.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.1K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.5K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.1K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K